News & Resources


Corporate Profile

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is NB32 (naltrexone sustained release (SR) / bupropion SR). Based on successful results of the Light Study, an ongoing cardiovascular outcomes trial, Orexigen's strategy for NB32 is to pursue approvals worldwide and pharmaceutical partnerships for global commercialization. The Company hasMore >>

Stock Quote

OREX (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Down 0.08 (1.49%)
Apr 17, 2014 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote

Recent News

More >>
03/12/14Orexigen Therapeutics Reports Corporate and Financial Results for the Fourth Quarter and Year Ended December 31, 2013Printer Friendly Version
03/03/14Orexigen Therapeutics to Host Full Year and Fourth Quarter 2013 Financial Results Conference Call and WebcastPrinter Friendly Version
02/27/14Orexigen Therapeutics to Present at the 34th Annual Cowen and Co. Health Care ConferencePrinter Friendly Version
02/25/14Orexigen Provides Update on Its NB32 European Marketing Authorization ApplicationPrinter Friendly Version

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.